A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs Evinacumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms ELIPSE HoFH
- Sponsors Regeneron Pharmaceuticals
- 05 Dec 2019 Planned End Date changed from 5 Apr 2020 to 13 Apr 2020.
- 05 Dec 2019 Status changed from recruiting to active, no longer recruiting.
- 14 Aug 2019 According to a Regeneron Pharmaceuticals media release, Detailed results from this trial will be presented at a future medical meeting and data will be submitted to regulatory authorities, starting with the FDA in 2020.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History